Literature DB >> 19249679

Oncogenic function of ATDC in pancreatic cancer through Wnt pathway activation and beta-catenin stabilization.

Lidong Wang1, David G Heidt, Cheong J Lee, Huibin Yang, Craig D Logsdon, Lizhi Zhang, Eric R Fearon, Mats Ljungman, Diane M Simeone.   

Abstract

Pancreatic cancer is a deadly disease characterized by late diagnosis and resistance to therapy. Much progress has been made in defining gene defects in pancreatic cancer, but a full accounting of its molecular pathogenesis remains to be provided. Here, we show that expression of the ataxia-telangiectasia group D complementing gene (ATDC), also called TRIM29, is elevated in most invasive pancreatic cancers and pancreatic cancer precursor lesions. ATDC promoted cancer cell proliferation in vitro and enhanced tumor growth and metastasis in vivo. ATDC expression correlated with elevated beta-catenin levels in pancreatic cancer, and beta-catenin function was required for ATDC's oncogenic effects. ATDC was found to stabilize beta-catenin via ATDC-induced effects on the Disheveled-2 protein, a negative regulator of glycogen synthase kinase 3beta in the Wnt/beta-catenin signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249679      PMCID: PMC2673547          DOI: 10.1016/j.ccr.2009.01.018

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  31 in total

1.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Authors:  Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; Athanasios Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

Review 2.  Progression model for pancreatic cancer.

Authors:  R H Hruban; M Goggins; J Parsons; S E Kern
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

3.  Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling.

Authors:  J Luo; D J Duggan; Y Chen; J Sauvageot; C M Ewing; M L Bittner; J M Trent; W B Isaacs
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 4.  The Wnt signaling pathway and its role in tumor development.

Authors:  B Lustig; J Behrens
Journal:  J Cancer Res Clin Oncol       Date:  2003-04-18       Impact factor: 4.553

5.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

6.  Wnt signaling controls the phosphorylation status of beta-catenin.

Authors:  Mascha van Noort; Jan Meeldijk; Ruurd van der Zee; Olivier Destree; Hans Clevers
Journal:  J Biol Chem       Date:  2002-02-07       Impact factor: 5.157

7.  Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation.

Authors:  G L Mutter; J P Baak; J T Fitzgerald; R Gray; D Neuberg; G A Kust; R Gentleman; S R Gullans; L J Wei; M Wilcox
Journal:  Gynecol Oncol       Date:  2001-11       Impact factor: 5.482

8.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer.

Authors:  Craig D Logsdon; Diane M Simeone; Charles Binkley; Thiruvengadam Arumugam; Joel K Greenson; Thomas J Giordano; David E Misek; Rork Kuick; Samir Hanash
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent.

Authors:  Tatjana Crnogorac-Jurcevic; Edoardo Missiaglia; Ekaterina Blaveri; Rathi Gangeswaran; Melanie Jones; Benoit Terris; Eithne Costello; John P Neoptolemos; Nicholas R Lemoine
Journal:  J Pathol       Date:  2003-09       Impact factor: 7.996

10.  Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease.

Authors:  Eva LaTulippe; Jaya Satagopan; Alex Smith; Howard Scher; Peter Scardino; Victor Reuter; William L Gerald
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  112 in total

1.  PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Authors:  Hongwu Zheng; Haoqiang Ying; Ruprecht Wiedemeyer; Haiyan Yan; Steven N Quayle; Elena V Ivanova; Ji-Hye Paik; Hailei Zhang; Yonghong Xiao; Samuel R Perry; Jian Hu; Anant Vinjamoori; Boyi Gan; Ergun Sahin; Milan G Chheda; Cameron Brennan; Y Alan Wang; William C Hahn; Lynda Chin; Ronald A DePinho
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

Review 2.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  SRI36160 is a specific inhibitor of Wnt/β-catenin signaling in human pancreatic and colorectal cancer cells.

Authors:  Yonghe Li; Patsy G Oliver; Wenyan Lu; Vibha Pathak; Sivaram Sridharan; Corinne E Augelli-Szafran; Donald J Buchsbaum; Mark J Suto
Journal:  Cancer Lett       Date:  2016-12-30       Impact factor: 8.679

4.  Xenopus skip modulates Wnt/beta-catenin signaling and functions in neural crest induction.

Authors:  Ying Wang; Yu Fu; Lei Gao; Guixin Zhu; Juan Liang; Chan Gao; Binlu Huang; Ursula Fenger; Christof Niehrs; Ye-Guang Chen; Wei Wu
Journal:  J Biol Chem       Date:  2010-01-26       Impact factor: 5.157

5.  TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin.

Authors:  Yasushi Masuda; Hidehisa Takahashi; Shigeo Sato; Chieri Tomomori-Sato; Anita Saraf; Michael P Washburn; Laurence Florens; Ronald C Conaway; Joan W Conaway; Shigetsugu Hatakeyama
Journal:  Nat Commun       Date:  2015-06-22       Impact factor: 14.919

6.  ATDC (Ataxia Telangiectasia Group D Complementing) Promotes Radioresistance through an Interaction with the RNF8 Ubiquitin Ligase.

Authors:  Huibin Yang; Phillip L Palmbos; Lidong Wang; Evelyn H Kim; Gina M Ney; Chao Liu; Jayendra Prasad; David E Misek; Xiaochun Yu; Mats Ljungman; Diane M Simeone
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

7.  Prognostic value of tripartite motif containing 29 expression in patients with gastric cancer following surgical resection.

Authors:  Chenghu Wang; Yi Zhou; Beibei Chen; Weiwei Yuan; Jinxi Huang
Journal:  Oncol Lett       Date:  2018-02-15       Impact factor: 2.967

8.  Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells.

Authors:  Fieke E M Froeling; Tariq A Mirza; Roger M Feakins; Angela Seedhar; George Elia; Ian R Hart; Hemant M Kocher
Journal:  Am J Pathol       Date:  2009-07-16       Impact factor: 4.307

9.  ATDC/TRIM29 phosphorylation by ATM/MAPKAP kinase 2 mediates radioresistance in pancreatic cancer cells.

Authors:  Lidong Wang; Huibin Yang; Phillip L Palmbos; Gina Ney; Taylor Ann Detzler; Dawn Coleman; Jacob Leflein; Mary Davis; Min Zhang; Wenhua Tang; J Kevin Hicks; Corey M Helchowski; Jayendra Prasad; Theodore S Lawrence; Liang Xu; Xiaochun Yu; Christine E Canman; Mats Ljungman; Diane M Simeone
Journal:  Cancer Res       Date:  2014-01-27       Impact factor: 12.701

10.  Proteomic profiling of human keratinocytes undergoing UVB-induced alternative differentiation reveals TRIpartite Motif Protein 29 as a survival factor.

Authors:  Véronique Bertrand-Vallery; Nathalie Belot; Marc Dieu; Edouard Delaive; Noëlle Ninane; Catherine Demazy; Martine Raes; Michel Salmon; Yves Poumay; Florence Debacq-Chainiaux; Olivier Toussaint
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.